Compare NAKA & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NAKA | UNCY |
|---|---|---|
| Founded | 2019 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.1M | 150.1M |
| IPO Year | 2023 | 2021 |
| Metric | NAKA | UNCY |
|---|---|---|
| Price | $9.97 | $4.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $0.75 | ★ $25.67 |
| AVG Volume (30 Days) | 207.4K | ★ 718.0K |
| Earning Date | 05-20-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.19 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | $1,514.38 | N/A |
| Revenue Next Year | $48.27 | $582.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $3.93 |
| 52 Week High | $10.27 | $8.74 |
| Indicator | NAKA | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 70.27 | 39.06 |
| Support Level | $0.24 | $3.93 |
| Resistance Level | N/A | $5.86 |
| Average True Range (ATR) | 0.60 | 0.23 |
| MACD | 0.08 | -0.02 |
| Stochastic Oscillator | 90.41 | 9.50 |
Nakamoto Inc is a Bitcoin company building a world-wide portfolio of Bitcoin-native companies to provide commercial and financial infrastructure for the next generation of capital markets. The firm has two principal business segments: Bitcoin Operations, which houses its Bitcoin treasury and is utilized to support investments in other Bitcoin-related companies; Healthcare Operations, which provides a patient-focused healthcare experience that provides patients personalized solutions in order to reduce opioid use and improve health outcomes. The company generates the majority of its revenue from the Healthcare Operations.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.